KalVista Pharmaceuticals
Stock Forecast, Prediction & Price Target
KalVista Pharmaceuticals (KALV) stock Price Target by analysts
$22.67
Potential upside: 76.94%
KalVista Pharmaceuticals price prediction
What is KalVista Pharmaceuticals stock analysts` prediction?
KalVista Pharmaceuticals stock forecast: Based on 3 Wall Street analysts` predicted price targets for KalVista Pharmaceuticals in the last 3 months, the avarage price target is $22.67, with a high forecast of $NaN. The average price target represents a 76.94% change from the last price of $12.81.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
KalVista Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given KalVista Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Serge Belanger Needham | 0% 0/1 | 10 months ago | $28 118.57% upside | $11.25 | StreetInsider | Previous targets (0) |
Joseph Schwartz Leerink Partners | 0% 0/1 | 12 months ago | $20 56.12% upside | $12.87 | StreetInsider | Previous targets (0) |
Andrew Fein H.C. Wainwright | 0% 0/1 | 12 months ago | $20 56.12% upside | $12.87 | StreetInsider | Previous targets (0) |
Unknown Leerink Partners | N/A | about 3 years ago | $45 251.28% upside | $11.07 | Benzinga | N/A |
Unknown Needham | N/A | about 3 years ago | $38 196.64% upside | $10.98 | Benzinga | N/A |
Unknown Stifel Nicolaus | N/A | about 3 years ago | $32 149.80% upside | $8.85 | Benzinga | N/A |
KalVista Pharmaceuticals Financial Estimates
KalVista Pharmaceuticals Revenue Estimates
KalVista Pharmaceuticals EBITDA Estimates
KalVista Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 4/30/2022 | 4/30/2023 | 4/30/2024 | 4/30/2026 | 4/30/2027 | 4/30/2028 | |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $118.32M Low: $71.84M High: $205.19M avg. 0% | Avg: $165.65M Low: $100.58M High: $287.28M avg. 40.00% | Avg: $230.40M Low: $139.89M High: $399.56M avg. 39.08% | |
Net Income
% change YoY
| $-68.51M N/A | $-74.85M -9.25% | $-126.64M -69.19% | Avg: $-25.81M Low: $-46.57M High: $29.00M avg. 79.61% | Avg: $8.54M Low: $-15.06M High: $33.19M avg. 133.10% | Avg: $42.48M Low: $20.79M High: $83.03M avg. 397.13% | |
EBITDA
% change YoY
| $-94.51M N/A | $-92.10M 2.54% | $-134.28M -45.79% | Avg: $-23.66M Low: $-41.03M High: $-14.36M avg. 82.37% | Avg: $-33.13M Low: $-57.45M High: $-20.11M avg. -40.00% | Avg: $-46.08M Low: $-79.91M High: $-27.97M avg. -39.08% | |
EPS
% change YoY
| -$2.8 N/A | -$2.68 4.28% | -$3.44 -28.35% | Avg: -$0.5 Low: -$1.67 High: $1.04 avg. 85.53% | Avg: $0.18 Low: -$0.54 High: $1.19 avg. 136.18% | Avg: $1.52 Low: $0.75 High: $2.98 avg. 746.29% | |
Operating Expenses
% change YoY
| $96.61M N/A | $110.87M 14.75% | $54.27M -51.04% | Avg: $118.68M Low: $72.06M High: $205.82M avg. 118.65% | Avg: $166.16M Low: $100.89M High: $288.16M avg. 40.00% | Avg: $231.10M Low: $140.32M High: $400.78M avg. 39.08% | |
FAQ
What is KalVista Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 203.28% in 2026-2028.
We have gathered data from 4 analysts. Their low estimate is -46.57M, average is -25.81M and high is 29.00M.
What is KalVista Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 26.36% in 2026-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $71.84M, average is $118.32M and high is $205.19M.
What is KalVista Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 322.67% in 2026-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$1.67, average is -$0.5 and high is $1.04.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering KalVista Pharmaceuticals stock. The most successful analyst is Serge Belanger.